{"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"groups":[{"description":"IV Busulfan + 12 cGy FTBI + VP16 prior to allogeneic Bone Marrow Transplant\n\nbusulfan\n\ncyclosporine\n\netoposide\n\nmycophenolate mofetil\n\nallogeneic bone marrow transplantation\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation\n\ntotal-body irradiation","id":"BG000","title":"Busulfan, FTBI and VP16"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"19","upperLimit":"50","value":"37"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"Hispanic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"White, Not Hispanic"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"22","upperLimit":"34","value":"26"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}]}],"description":"A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144(6):407-414. Parimon T, Au DH, Martin PH, Chien JW. \"We generated 4 categories of PAM scores by setting cutoffs according to the probability of death. Scores ranged from 9 to 16 for category 1 (probability of death, \\< 25%), from 17 to 23 for category 2 (probability of death, 25% to 50%), from 24 to 30 for category 3 (probability of death, 50% to 75%), and from 31 to 44 for category 4 (probability of death, \\> 75%).\"","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Patient Assessment of Mortality (PAM) Score","unitOfMeasure":"units on a scale"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"AML in First Complete Remission"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"AML in First Relapse"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"AML in Induction Failure"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"untreated RAEB-t"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"ALL in First Relapse"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"ALL in Second Relapse"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"ALL in Induction Failure"}],"description":"Disease classification was based on WHO criteria \\[Vardiman, Blood 2002\\]: Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), and untreated refractory anemia with excess blasts in transformation (RAEB-t).","paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Status at Transplant","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"Indeterminate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"Intermediate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"Unfavorable"}],"description":"Cytogenetics were based on Southwest Oncology Group criteria \\[Leith CP, Blood 1997; Pullarkat V, Blood 2008\\].\n\nIntermediate: normal and all other cytogenetic abnormalities. Unfavorable: -5/5q-, -7/7q-, inv(3), 11q abn, 17p abn or i(17q), del(20q), dmins/hsrs, +13, t(9; 22), complex (\\>3 abn) karyotypes.\n\nIndeterminate: all other clonal cytogenetic abnormalities.","paramType":"COUNT_OF_PARTICIPANTS","title":"Cytogenetics","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"Bone Marrow"},{"categories":[{"measurements":[{"groupId":"BG000","value":"29"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"title":"Peripheral Blood"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Stem Cell Source","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.9","upperLimit":"29.2","value":"3.4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"24"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","populationDescription":"Patients with active disease","title":"WBC pre-conditioning","unitOfMeasure":"x10^9 cells/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0","upperLimit":"95","value":"16.5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"24"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","populationDescription":"Patients with active disease","title":"Percent Blasts in Bone Marrow","unitOfMeasure":"percent of leukocytes"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0","upperLimit":"92","value":"3.5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"24"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","populationDescription":"Patients with Active Disease","title":"Percent Blasts in Peripheral Blood","unitOfMeasure":"percent of leukocytes"}],"populationDescription":"Enrolled on protocol after screening for eligiblility"}